TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05307705
Drug: Anastrozole, Exemestane, or Letrozole
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05307705
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous
Study: NCT06285201
Drug: T
Normalized name: TG
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
Study: NCT05322512
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
Study: NCT06108726
Drug: Envafolimab Injection
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
Study: NCT06087237
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg pentoxifylline oral tablets three times per day starting from the day before surgery till two weeks after the surgery.
Study: NCT05160168
Drug: THE-630
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THE-630 administered once daily in a continuous regimen
Study: NCT04985500
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mL of 0.25% bupivacaine
Study: NCT05055323
Drug: Pyrvinium Pamoate
Normalized name: Pyrvinium Pamoate
DrugBank: Pyrvinium (DB06816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04597359
Drug: Sinecatechins
Normalized name: Sinecatechins
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05359874
Drug: Bevacizumab-IRDye800CW
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
Study: NCT05047939
Drug: remimazolam-based TIVA
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
Study: NCT05047939
Drug: propofol-based TIVA
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
Study: NCT03692754
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin will be given in 20 mg po qn for 1 month
Study: NCT03692754
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin will be given in 10 mg po qn for 1 month
Study: NCT03692754
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be given in 40mg po qd for 4 days
Study: NCT05706727
Drug: Intravenous bolus dose of Mephentermine and mephentermine
Normalized name: mephentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous bolus dose of mephenteramine 6mg
Study: NCT05706727
Drug: intravenous bolus dose of phenylephrine 50 mcg
Normalized name: OIL OF CAMPHOR
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous bolus dose of phenylephrine 50 mcg
Study: NCT02939820
Drug: patisiran (ALN-TTR02)
Normalized name: patisiran
DrugBank: Patisiran (DB14582)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patisiran (ALN-TTR02) administered by intravenous (IV) infusion
Study: NCT05311176
Drug: Ramucirumab plus Paclitaxel
Normalized name: Ramucirumab
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
Study: NCT06115473
Drug: isotonic fluid
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive IV bolus isotonic fluid 500 ml
Study: NCT05190315
Drug: Chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide.
Study: NCT05190315
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle.
Study: NCT01140100
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01140100
Drug: thiopental,propofol
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05570110
Drug: Enoxolone
Normalized name: Enoxolone
DrugBank: Enoxolone (DB13089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule of active or placebo in the evening
Study: NCT05653310
Drug: Tradipitant
Normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tradipitant Capsule
Study: NCT05872542
Drug: Silver Diamine Fluoride (SDF)
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
Study: NCT05594927
Drug: Icaritin
Normalized name: Icaritin
DrugBank: Icaritin (DB12672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
Study: NCT06314373
Drug: HSK39775 Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK39775 will be administered orally once daily
Study: NCT04961528
Drug: Tranexamic Acid 500 MG
Normalized name: tranexamic acid 500 MG
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days
Study: NCT04961528
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days
Study: NCT05758389
Drug: Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: evaluate the efficacy and safety of immunotherapy combined with chemotherapy
Study: NCT05349409
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 for Injection: Given IV.
Study: NCT05349409
Drug: Fluzoparib Capsule
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib Capsule: Given PO.
Study: NCT05131867
Drug: nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (60 mg/4 hours) orally or via nasogastric tube
Study: NCT05131867
Drug: Oral Nimodipine and milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
Study: NCT04754191
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
Study: NCT04999384
Drug: AN4005-dose level 0
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg BID
Study: NCT04999384
Drug: AN4005-dose level 1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg BID
Study: NCT04999384
Drug: AN4005-dose level 2
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID
Study: NCT04999384
Drug: AN4005-dose level 3
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg BID
Study: NCT04999384
Drug: AN4005-dose level 4
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg BID
Study: NCT04999384
Drug: AN4005-food effect
Normalized name: Allergenic extract, food, wheat
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be determined upon the MTD determination
Study: NCT04683146
Drug: Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later.
Study: NCT04366830
Drug: Remestemcel-L
Normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
Study: NCT06554535
Drug: Serplulimab，Platinum-based Chemotherapy，Aspirin
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
Study: NCT05582707
Drug: Pioglitazone 15mg
Normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
Study: NCT00002389
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002389
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002389
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06503848
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Register the response to treatment and headache characteristics.
Study: NCT05389514
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
Study: NCT05389514
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
Study: NCT06040424
Drug: Ipratropium + Levosalbutamol Free Dose Combination
Normalized name: ipratropium Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free combination control treatment
Study: NCT06662318
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.
Study: NCT06662318
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
Study: NCT06659692
Drug: Gonadotropins Subcutaneous
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropins s.c. multiple dose
Study: NCT04974827
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg/3weeks
Study: NCT04974827
Drug: Cisplatin or Carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
Study: NCT04577300
Drug: NT-501
Normalized name: NT-501
DrugBank: Ciliary neurotrophic factor (DB05344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant of Neurotech NT-501 device(s)
Study: NCT00633373
Drug: Cyclosporine Inhalation Solution
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
Study: NCT00367718
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
Study: NCT04085653
Drug: alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed.
Study: NCT05340868
Drug: Semaglutide Pill
Normalized name: semaglutide Pill
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral semaglutide treatment
Study: NCT06096870
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)
Study: NCT04537026
Drug: Amniotic Fluid Allograft
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach
Study: NCT04537026
Drug: Dexamethasone sodium phosphate
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone phosphate mixed with sterile water will be injected by transforaminal approach
Study: NCT04878627
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients receive cannabidiol at various doses for 3 weeks
Study: NCT06532071
Drug: Gadoterate Meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI
Study: NCT05775159
Drug: Volrustomig
Normalized name: Volrustomig
DrugBank: Volrustomig (DB18893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA-4/Anti-PD-1 Bispecific Antibody
Study: NCT05775159
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Study: NCT05775159
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Study: NCT05775159
Drug: Rilvegostomig
Normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti- PD-1 and TIGIT bispecific antibody
Study: NCT05775159
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, IV infusion
Study: NCT05775159
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2, IV infusion
Study: NCT06000462
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mentioned in detailed description.
Study: NCT06000462
Drug: Metformin 1000 mg (ttd)
Normalized name: metformin 1000 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A dose of 1000 mg, PO, once daily, given over 8 months period
Study: NCT06111586
Drug: Frexalimab
Normalized name: Frexalimab
DrugBank: Frexalimab (DB18926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102
Study: NCT06111586
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC injection, dose and frequency will be established and/or adjusted by investigator
Study: NCT05828108
Drug: Bitopertin
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
Study: NCT06190951
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenous (IV) every 3 weeks (Q3W) Phase 3 active comparator
Study: NCT06190951
Drug: fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV Q3W Phase 2
Study: NCT06190951
Drug: cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IV Q3W Phase 2 Active Comparator
Study: NCT06190951
Drug: cemiplimab+fianlimab
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IV Q3W Phase 3 Either fianlimab HD or fianlimab LD in combination with cemiplimab will be chosen for Phase 3